Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping

Autor: Julia Almeida, Carlos E. Pedreira, M del Carmen García-Macias, Juan Flores, Sandra Quijano, Quentin Lecrevisse, Alberto Orfao, S Böttcher, Susana Barrena, J. J. M. Van Dongen, Elaine Sobral da Costa
Přispěvatelé: Immunology
Jazyk: angličtina
Rok vydání: 2011
Předmět:
Zdroj: Leukemia
Digital.CSIC. Repositorio Institucional del CSIC
instname
Europe PubMed Central
Leukemia, 24(11), 1927-1933. Nature Publishing Group
ISSN: 1476-5551
0887-6924
Popis: 7 páginas, 1 figura, 2 tablas.-- This work is licensed under the Creative Commons Attribution-NonCommercial-No Derivative Works 3.0 Unported License.-- et al.
Immunophenotypic characterization of B-cell chronic lymphoproliferative disorders (B-CLPD) is becoming increasingly complex due to usage of progressively larger panels of reagents and a high number of World Health Organization (WHO) entities. Typically, data analysis is performed separately for each stained aliquot of a sample; subsequently, an expert interprets the overall immunophenotypic profile (IP) of neoplastic B-cells and assigns it to specific diagnostic categories. We constructed a principal component analysis (PCA)-based tool to guide immunophenotypic classification of B-CLPD. Three reference groups of immunophenotypic data filesB-cell chronic lymphocytic leukemias (B-CLL; n10), mantle cell (MCL; n10) and follicular lymphomas (FL; n10)were built. Subsequently, each of the 175 cases studied was evaluated and assigned to either one of the three reference groups or to none of them (other B-CLPD). Most cases (89%) were correctly assigned to their corresponding WHO diagnostic group with overall positive and negative predictive values of 89 and 96%, respectively. The efficiency of the PCA-based approach was particularly high among typical B-CLL, MCL and FL vs other B-CLPD cases. In summary, PCA-guided immunophenotypic classification of B-CLPD is a promising tool for standardized interpretation of tumor IP, their classification into well-defined entities and comprehensive evaluation of antibody panels. © 2010 Macmillan Publishers Limited All rights reserved.
This work has been partially supported by the following Grants: Spanish Network of Cancer Research Centers (ISCIII RTICCRD06/0020/0035-FEDER), FIS 08/90881 from the ‘Fondo de Investigación Sanitaria’, Ministerio de Ciencia e Innovación (Madrid, Spain), Programa Hispano-Brasileño de Cooperación Universitaria Ref. PHB 2004-0800-PC (Ministerio de Educación y Ciencia) (Madrid, Spain), SA016-A-09 from the Consejería de Educación, Junta de Castilla y León, Valladolid, Spain, and CAPES/Ministério da Educaçâo (Brasília, Brazil), the EuroFlow Consortium (Grant number LSHB-CT-2006-018708), from the European Commission and by the ‘Accio´n Transversal del Cáncer’ project through an agreement between the Instituto de Salud Carlos III (ISCIII), Ministerio de Ciencia e Innovación (Madrid, Spain) and the Cancer Research Foundation of the University of Salamanca (Salamanca, Spain). CEP and ESC were partially supported by a grant from CNPq- Brazilian National Research Council, Brası´lia, Brazil (Ref: 305306/2004-9, 558147/2008-9 PDP and 478234/2007-4) and FAPERJ-Fundaçâo de amparo à pesquisa do Rio de Janeiro, (Rio de Janeiro, Brazil) ‘Pensa-Rio’ project E-26/110.301/2007, E-26/102-781/2008 CNE and ‘Jovens Pesquisadores’ no 03/2006). CEP and ESC were partially supported by a grant from Fundación Carolina, Spain. QL was supported by a grant from Fundació Marcelino Botín (Madrid, Spain).
Databáze: OpenAIRE
Externí odkaz: